the submissions that failed to demonstrate efficacy (52%). Characteristics associated with a FFR being a biologic product, having an appropriate comparator, showing sufficient clinical evidence and being priced at a similar/lower price than the comparator. **CONCLUSIONS:** The presence of patient input was not associated with a FFR. The lack of significant association could be attributed to external factors including price and the presence of other factors in CMS's summary reports and the limited sample size of data available. It remains unclear how patient input is integrated into the decision making process.

### HEALTH CARE USE & POLICY STUDIES – Disease Management

**PHP6**

**STUDY OF THE SANITARY GEOGRAPHY OF COLOMBIA: A BIG DATA APPROACH**

**Fier C**, Jaramillo LF, Franco C

Ministry of Health and Social Protection, Bogota, Colombia

**OBJECTIVES:** This study aims to propose a new geographic administrative organization of Colombian municipalities for health care management purposes. Rather than responding to arbitrary political boundaries, this division should answer to health needs and capacities, in order to facilitate the development of targeted policies to reach universal coverage and improve access to health services. **METHODS:** To achieve this, a big data was created: it contains information about different health-affecting topics: economic development, socio-cultural background, public and transportation services, environmental conditions and health indicators, supply and demand. These topics were measured with over 70 variables. After that, using a principal-component analysis, one or two indicators were created per topic. These indicators were used to build clusters that allow developed sanitary regions. Afterwards, another study was made in which people were tracked from their residence to the places where they received health services. Then, the country was divided into different regions reflecting the migration flows. Finally, the study mingle both information - the clusters and migration networks- to determine a sanitary geography of Colombia. **RESULTS:** Using the methodology, this study proposes a new administrative model that are statistically significant and consistent with the reality of Colombia. Also, many networks were proposed, but 5 of them represented the national situation closely. Combining these alternatives, the study achieves its goal and creates a satisfactory segmentation of the country that is valuable for public policy. **CONCLUSIONS:** The proposed categories serve well the needs that originated this study and are an appropriate framework for health care management purposes. In fact, the Colombian Ministry of Health has used it as an input for telemedicine and first infancy projects and health care reform. Its main conclusion is that health cannot be worked using political divisions. It is fundamental to use supply, demand and context criteria to determine regions useful for policymakers.

### PHP9

**UNDERSTANDING STAKEHOLDER PERSPECTIVES ON MEDICARE’S COVERAGE WITH EVIDENCE DEVELOPMENT (CED) POLICY**

**Geoffrey J**, Loew C, Walsh EM, Williams R

Access Partnership LLC, Washington, DC, USA

**OBJECTIVES:** To understand key stakeholder recommendations for the Centers for Medicare & Medicaid Services (CMS) regarding the application of its CED policy, the current CED process and its potential coverage determination process. Specifically, 17 stakeholders called on CMS to prohibit CED at the local level and restrict its application to the NCD process while 12 stakeholders recommended CMS to provide clear timelines for the duration of CED studies. In addition, 11 stakeholders requested clarity from CMS on how it intends to collaborate with the Food and Drug Administration (FDA) on post-market evidence requirements, urging that CED should not duplicate or replace FDA’s authority. **METHODS:** A total volume of 322 billion a year, Japan is the world’s second largest market behind the US. It imports about 35% of the medical devices from abroad. Although imports have been increasing steadily over the past years, Japan still struggles to have similar access to advanced medical devices as the US and Europe. This research aimed to have a closer look at the Japanese medical device market, and further explore access barriers. **RESULTS:** This research was conducted through in-depth secondary research and interviews with a variety of stakeholders including payers, academics, and KOLs in Japan. **CONCLUSIONS:** It is important for foreign manufacturers to understand the implications of the Japanese regulatory barriers and address them in their foreign market strategies allowing them to assess product viability early on.

### PHP10

**PRICE DYNAMICS OF EXTERNAL REFERENCE PRICING-BASED SYSTEMS IN EUROPE**

**Ménard C**, Vataire AL2, Orhinatti D3, Kornfeld A4, Toumi M5

Access Partnership LLC, Paris, France. **OBJECTIVES:** The authors analyzed stakeholder comments submitted on CMS’s Medicare Coverage Database and assessed to understand key positions on issues related to the CED process. **RESULTS:** Of the 27 stakeholders who submitted comments to CMS, over half were from the life sciences industries. The majority of stakeholders called for CMS to provide more clarity on how the agency plans to address operational issues with CED implementation. Stakeholders who may be impacted by the issuance of a CED, such as manufacturers, are seeking greater transparency from CMS on policies and processes for applying CED as well as greater clarity on the parameters for executing CED studies. Specifically, 17 stakeholders called on CMS to prohibit CED at the local level and restrict its application to the NCD process while 12 stakeholders recommended CMS to provide clear timelines for the duration of CED studies. In addition, 11 stakeholders requested clarity from CMS on how it intends to collaborate with the Food and Drug Administration (FDA) on post-market evidence requirements, urging that CED should not duplicate or replace FDA’s authority. **CONCLUSIONS:** Going forward, CMS will likely continue to invoke CED with increasing frequency and potentially on a broader range of products. Therefore, clearer guidance from CMS is critical to ensuring continued stakeholder engagement through Medicare’s coverage determination process.

### PHP8

**A LONG WAR BEGINS: BIOSIMILARS VERSUS PATENTED BIOLOGICS – A RETROSPECTIVE ANALYSIS OF THE EU-5 AND JAPANESE ERYTHROPOIETINS MARKETS**

**Bouquet P1, Pauwel P1, Fusier I1, Cordonnier AI1, Le Pen C2, Sinha Roy M3**

1Daphne University, Paris, France. 2Paris Descartes University, Paris, France. 3General Agency of Equipment of Health, Agriculture and Foodstuffs (AGEPS), AP-HP, Paris, France. 4General Agency of Equipment of Health Products (AGEPS), Public Welfare Hospital of Paris (AP-HP), Paris, France

**OBJECTIVES:** Analyze factors influencing Erythropoietins (EPO) biosimilars (copies of patented EPO (Biosim-EPO) uptakes in key global markets. Identify, if possible, country profiles where BIOSIM-EPO have taken market shares. **METHODS:** Countries inclusion criteria: legal definition and regulatory framework for biosimilars close to the EU; at least 3 years of experience with BIOSIM-EPO in 2012; national biological market value higher than US$ 2.5 billion. Factors evaluated: national EPO market sizes, EPO retail/hospital distribution mixes, existence of policy incentives (taxes, reimbursement, regulations of biosim-EPO product prices relative to reference EPO. Data on medicine volumes, values and ex-manufacturer prices for all EPOs (alfa, BIOSIM-EPO (EPO alfa biosimilar), beta and second-generation biosimilars) were provided. Voluntary volumes were calculated in DDD (Defined Daily Doses) and prices in euros per DDD. Data were available from 2007 until 2012. **RESULTS:** EU-5 and Japan have been included. Germany: small-sized market, dominant retail market distribution, incentives to prescribe BIOSIM-EPO (equivalent to ‘substitute patented for biodepoticals’ EPO, high BIOSIM-EPO uptakes (30.4% in 2012). In Spain and Italy: medium-sized markets, dominant hospital distribution, no incentives, 11% 5% and 8.6% BIOSIM-EPO uptake: respectively. Japan: the largest market, mixed distribution channels, no incentives, 5.8% BIOSIM-EPO uptake. **CONCLUSIONS:** This study proved that EPO markets are highly specific. There is no single specific profile for countries in which BIOSIM-EPO have significantly penetrated the market. Providing national prescription and substitution incentives is the only determining factor for BIOSIM-EPO uptakes. National EPO market sizes, EPO retail/hospital distribution mixes and BIOSIM-EPO prices relative to reference EPO are not significant factors.

### PHP11

**TIME LAGS FROM FDA DRUG APPROVAL TO PUBLICATION OF COST-UTILITY ANALYSIS**

**Bettles AM, Towill T1, Chambers JD, Neumann P2,3**

1Tufts Medical Center, Boston, MA, USA. 2Tufts Medical Center, Boston, MA, USA. 3Tufts Medical Center, Boston, MA, USA

**OBJECTIVES:** Cost-utility analysis (CUA) provides valuable information on the value of medical technology and is used by many payers to inform coverage and reimbursement decisions. The time lag from FDA approval to publication of CUA can be used to measure the impact of the approval process. **METHODS:** A11